255 related articles for article (PubMed ID: 24637537)
1. Androgen dynamics and serum PSA in patients treated with abiraterone acetate.
Ryan CJ; Peng W; Kheoh T; Welkowsky E; Haqq CM; Chandler DW; Scher HI; Molina A
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):192-8. PubMed ID: 24637537
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
3. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
Kim W; Zhang L; Wilton JH; Fetterly G; Mohler JL; Weinberg V; Morse A; Szmulewitz RZ; Friedlander TW; Fong L; Lin AM; Harzstark AL; Molina A; Small EJ; Ryan CJ
Clin Cancer Res; 2014 Dec; 20(24):6269-76. PubMed ID: 25336698
[TBL] [Abstract][Full Text] [Related]
4. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
[TBL] [Abstract][Full Text] [Related]
5. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
[TBL] [Abstract][Full Text] [Related]
6. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Omlin A; Pezaro C; Atenafu EG; Keizman D; Vera-Badillo F; Seah JA; Attard G; Knox JJ; Sridhar SS; Tannock IF; de Bono JS; Joshua AM
Ann Oncol; 2014 Mar; 25(3):657-662. PubMed ID: 24458472
[TBL] [Abstract][Full Text] [Related]
7. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ
Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
10. Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
Mostaghel EA; Marck BT; Kolokythas O; Chew F; Yu EY; Schweizer MT; Cheng HH; Kantoff PW; Balk SP; Taplin ME; Sharifi N; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2021 Nov; 27(21):6001-6011. PubMed ID: 34407973
[TBL] [Abstract][Full Text] [Related]
11. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
13. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
[TBL] [Abstract][Full Text] [Related]
14. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.
Ryan CJ; Molina A; Li J; Kheoh T; Small EJ; Haqq CM; Grant RP; de Bono JS; Scher HI
J Clin Oncol; 2013 Aug; 31(22):2791-8. PubMed ID: 23816964
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Posadas EM; Chi KN; de Wit R; de Jonge MJA; Attard G; Friedlander TW; Yu MK; Hellemans P; Chien C; Abrams C; Jiao JJ; Saad F
Clin Cancer Res; 2020 Jul; 26(14):3517-3524. PubMed ID: 32366670
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
17. Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.
Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; De Porre P; Vermeulen A; Poggesi I; Nandy P
Clin Pharmacokinet; 2017 Jan; 56(1):55-63. PubMed ID: 27324190
[TBL] [Abstract][Full Text] [Related]
18. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
Friedlander TW; Graff JN; Zejnullahu K; Anantharaman A; Zhang L; Paz R; Premasekharan G; Russell C; Huang Y; Kim W; Aggarwal RR; Lin AM; Fong L; Alumkal JJ; Beer TM; Sharifi N; Alyamani M; Dittamore R; Small EJ; Paris PL; Ryan CJ
Clin Genitourin Cancer; 2017 Dec; 15(6):733-741.e1. PubMed ID: 28655452
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Zhou ZR; Liu SX; Zhang TS; Xia J; Li B
Asian Pac J Cancer Prev; 2014; 15(3):1313-20. PubMed ID: 24606458
[TBL] [Abstract][Full Text] [Related]
20. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
Romero-Laorden N; Lozano R; Jayaram A; López-Campos F; Saez MI; Montesa A; Gutierrez-Pecharoman A; Villatoro R; Herrera B; Correa R; Rosero A; Pacheco MI; Garcés T; Cendón Y; Nombela MP; Van de Poll F; Grau G; Rivera L; López PP; Cruz JJ; Lorente D; Attard G; Castro E; Olmos D
Br J Cancer; 2018 Oct; 119(9):1052-1059. PubMed ID: 30131546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
